Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 24:10:573977.
doi: 10.3389/fonc.2020.573977. eCollection 2020.

Immunotherapy in Testicular Germ Cell Tumors

Katarina Kalavska  1   2 , Silvia Schmidtova  1   2 , Michal Chovanec  3 , Michal Mego  1   3
Affiliations
Review

Immunotherapy in Testicular Germ Cell Tumors

Katarina Kalavska et al. Front Oncol. .

Abstract

Testicular germ cell tumors (TGCTs) are malignancies with very high curative potential even in metastatic settings, mainly due to the introduction of cisplatin in the treatment of this disease. However, in a group of patients with cisplatin-refractory disease or with progressive disease despite high-dose salvage chemotherapy treatment, the prognosis is typically dismal. The triple combination of gemcitabine, oxaliplatin, and paclitaxel (GOP) has reasonable efficacy and is considered to be standard care for this group of patients. It remains to be seen, however, whether refractory TGCTs may represent a potential target for immune checkpoint inhibition. This review will focus on the rationale of the use of immunotherapy for platinum-refractory TGCTs and summarize data reporting experiences with immune checkpoint inhibitor treatment for this malignancy.

Keywords: cisplatin-resistance; immune checkpoint inhibitors; immune microenvironment; immunotherapy; testicular germ cell tumors.

PubMed Disclaimer

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492 - DOI - PubMed
    1. Moul JW, Paulson DF, Dodge RK, Walther PJ. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol. (1990) 143:520–3. 10.1016/S0022-5347(17)40007-3 - DOI - PubMed
    1. Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C. Testicular germ cell tumours. Lancet. (2016) 387:1762–74. 10.1016/S0140-6736(15)00991-5 - DOI - PubMed
    1. De Giorgi U, Rosti G, Salvioni R, Papiani G, Ballardini M, Pizzocaro G, et al. . Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features. Urol Oncol. (2011) 29:284–90. 10.1016/j.urolonc.2009.03.030 - DOI - PubMed
    1. Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, et al. . Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. (2012) 118:981–6. 10.1002/cncr.26375 - DOI - PubMed

LinkOut - more resources